Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 87 Show results per page	View Search Criteria \| Help With Results


1.		An Expanded Access Program For Lenalidomide Plus Dexamethasone In Previously Treated Subjects With Multiple Myeloma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Treatment				Active				18 and over				Pharmaceutical / Industry				CC-5013-MM-016 NCT00179647

Last Modified: 9/18/2008 First Published: 6/8/2005


2.		Phase III Randomized Study of Lenalidomide as Maintenance Therapy After Autologous Stem Cell Transplantation in Patients With Multiple Myeloma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 to 70				NCI				CALGB-100104 CALGB-100104, ECOG-CALGB-100104, NCT00114101


3.		A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				65 and over				Pharmaceutical / Industry				CC-5013-MM-015 NCT00405756


4.		Maintenance Therapy Using Lenalidomide in Myeloma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 to 65				Other				0400401 French PHRC, NCT00430365


5.		Revlimid (Lenalidomide) and Dexamethasone (ReDex) Treatment Versus Observation in Patients With Smoldering Multiple Myeloma With High Risk of Progression

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Other				2007-000649-36 QUIREDEX, NCT00480363

Last Modified: 9/17/2008 First Published: 8/25/2007


6.		Phase III Randomized Study of Consolidation Therapy Comprising Bortezomib and Dexamethasone With Versus Without Lenalidomide in Patients With Symptomatic Multiple Myeloma Who Have Completed a Dexamethasone-Based Induction Regimen

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				NCI				ECOG-E1A05 E1A05, NCT00522392


7.		Lenalidomide Melphalan and Prednisone Versus High Dose Melphalan in Newly Diagnosed Multiple Myeloma Patients

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 to 65				Other				SHEBA-07-4918-IH-CTIL NCT00551928

Last Modified: 9/18/2008 First Published: 1/17/2008


8.		Phase III Randomized Study of Melphalan, Prednisone, and Thalidomide Versus Melphalan, Prednisone, and Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Biomarker/Laboratory analysis, Natural history/Epidemiology, Treatment				Active				18 and over				NCI				ECOG-E1A06 E1A06, NCT00602641

Last Modified: 9/19/2008 First Published: 3/21/2008


9.		Phase III Randomized Study of Lenalidomide and Low-Dose Dexamethasone With Versus Without Bortezomib in Patients With Previously Untreated Multiple Myeloma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				NCI				SWOG-S0777 S0777, NCT00644228


10.		Study to Determine Efficacy and Safety of Lenalidomide Plus Low-Dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Approved-not yet active				18 and over				Pharmaceutical / Industry				CC-5013-MM-020 NCT00689936

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute